• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Report: Medtech tax has cost 33,000 jobs already

Report: Medtech tax has cost 33,000 jobs already

February 18, 2014 By Arezu Sarvestani

Survey: Medtech tax has cost 33,000 jobs already

The medical device industry has already lost some 33,000 jobs as a result of the medical device tax, according to a report from lobbying group AdvaMed.

Including indirect repercussions in related industries and the economy in general, AdvaMed estimated that as many as 165,000 jobs have been compromised due to the impact of the 2.3% medical device sales tax that took effect last year. The findings came from an AdvaMed survey of its member companies, using responses from 38 firms to extrapolate effects in the industry at large.

"Contrary to the claims of some of the proponents of this tax, companies are simply not able to pass the tax on and are not anticipating a windfall from expanded coverage," AdvaMed president & CEO Stephen Ubl said in a conference call with reporters today. "At a time when unemployment remains at historic highs and there is bipartisan interest in growing advanced manufacturing jobs here in America, our industry is experiencing an unprecedented real-world negative impact on jobs and R&D due to this tax."

In addition to layoffs, device makers slashed their R&D budgets, reduced employee pay, moved manufacturing overseas, reduced spending in start-ups, canceled or put off new facilities and took other actions to deal with the cost of the new levy, according to the report.

The results paralleled some findings from a recent Emergo Group survey that similarly reported lowered R&D spending and job losses in 2013 as a result of the medical device tax. The Emergo survey, however, also found that fewer medtech executives reported negative effects overall than had been expected. An increasing percentage reported that the tax had no impact on their company in 2013.

"Overall, the impact of the [medical device excise tax] is being felt by industry, but the impact seems to be less severe than depicted by the media and industry organizations," according to Emergo.

AdvaMed’s survey brought a far different message, highlighting that a significant number of survey respondents said that they slashed their R&D budgets, moved jobs overseas and took other undesirable steps in response to the tax. Looking forward, half said they would continue lowering R&D and 58% said they would consider additional layoffs if the tax were not repealed.

"As a start-up company getting ready to launch a product, the [medical device excise tax] will create a $300K potential debt/cash-flow problem," one anonymous respondent wrote. "I can’t afford to be successful!"

"We are likely to close a U.S. plant which will offset about 70-80% of the cost of the MDET," wrote another.

AdvaMed’s survey included companies from 17 U.S. states, representing offices and jobs in all 50 states. Companies were split about halfway between revenues under $100 million and those with higher sales, and 40% were operating at an annual loss. In total, the companies represented $35.5 billion in annual revenue, about 22% of the total industry.

The lobbying group has been actively fighting the medical device tax since its inception during discussions that shaped the Affordable Care Act, but has been stone-walled in part by difficulties finding a way to make up for lost federal revenues. The tax is slated to bring in about $30 billion to help fund healthcare reform, and AdvaMed and other industry groups have maintained that finding a so-called "pay-for" to replace that funding is a task best left to Congress.

"We’re ambivalent about the funding source for repeal," AdvaMed chairman and Zimmer Holdings (NYSE:ZMH) president & CEO David Dvorak said during today’s call. "This is a new year and potential pay-fors are yet to be identified. We, frankly, believe that it’s a matter that policy-makers ought to take on."

Repeal efforts have garnered significant attention and support from both sides of the aisle. A House bill to repeal the levy has 270 co-sponsors, including 43 Democrats, Dvorak said. The Senate version has 38 co-sponsors, including 6 Democrats.

Calls for repeal continue to gain lawmaker support, but previous pay-for proposals have rubbed Democrats the wrong way and President Barack Obama has on more than 1 occasion promised to veto a device tax repeal bill should one land on his desk. Former President Bill Clinton reiterated the importance of finding a pay-for, telling an audience of healthcare stakeholders in Laguna Beach, Calif., last monthly that efforts to repeal the medical device tax must come with a strategy to make up the lost funds.

"You’ve got medical device people, they hate the tax," Clinton said during January’s Patient Safety, Science & Technology Summit. "If you want to get rid of it you’ve got to say how you’d replace it."

Filed Under: News Well Tagged With: AdvaMed, Layoffs, Lobbying

In case you missed it

  • FDA clears Neurolief’s noninvasive neuromod tech to treat migraines
  • Could this hydrogel repair a broken heart?
  • Virta Health touts study of treatment preventing progression to Type 2 diabetes
  • Philips, DiA partner on AI-based applications for ultrasound
  • Cook Medical wins FDA breakthrough device designation for next-gen endovascular graft
  • FDA grants breakthrough nod to Anuncia’s cerebral spinal fluid treatment
  • Varian CEO Dow Wilson to retire after merger with Siemens Healthineers
  • Medtronic touts results of cardiac resynchronization therapy trial
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
  • Abbott researchers help discover a clue to an HIV cure
  • Q BioMed wins federal contract for bone cancer drug
  • Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
  • FDA accepts New Drug Application for Eyenovia pupil dilation tech
  • Axonics, Micro Systems Technologies partners to make rechargeable SNM device
  • Component Testing & Analysis: How to Gain Deeper Insights with a Universal Testing System
  • SeaSpine ticks up on 6.2% sales growth in Q4, reports losses
  • Boston Scientific completes Preventice buy, divests BTG Pharmaceutical business

RSS From Medical Design & Outsourcing

  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS